Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BG 68501 (Primary) ; BGB-43395 (Primary) ; Fulvestrant (Primary)
  • Indications Advanced breast cancer; Fallopian tube cancer; HER2 negative breast cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors BeOne Medicines

Most Recent Events

  • 01 Jun 2026 Planned End Date changed from 1 Jul 2028 to 31 Aug 2026.
  • 01 Jun 2026 Planned primary completion date changed from 1 Apr 2028 to 31 Aug 2026.
  • 01 Jun 2026 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top